Wendell Amy McBride 4
4 · Axogen, Inc. · Filed Dec 17, 2025
Insider Transaction Report
Form 4
Axogen, Inc.AXGN
Wendell Amy McBride
Director
Transactions
- Exercise/Conversion
Common Stock
2025-12-16$8.95/sh+5,000$44,750→ 98,826 total - Exercise/Conversion
Common Stock
2025-12-16$6.30/sh+20,436$128,747→ 119,262 total - Exercise/Conversion
Common Stock
2025-12-16$7.04/sh+18,248$128,466→ 137,510 total - Sale
Common Stock
2025-12-16$29.31/sh−5,000$146,560→ 132,510 total - Sale
Common Stock
2025-12-16$29.31/sh−20,436$599,020→ 112,074 total - Sale
Common Stock
2025-12-16$29.31/sh−18,248$534,885→ 93,826 total - Exercise/Conversion
Stock Option (right to purchase)
2025-12-16−5,000→ 0 totalExercise: $8.95Exp: 2026-12-29→ Common Stock (5,000 underlying) - Exercise/Conversion
Stock Option (right to purchase)
2025-12-16−20,436→ 0 totalExercise: $6.30Exp: 2033-09-01→ Common Stock (20,436 underlying) - Exercise/Conversion
Stock Option (right to purchase)
2025-12-16−18,248→ 0 totalExercise: $7.04Exp: 2034-06-06→ Common Stock (18,248 underlying)
Footnotes (4)
- [F1]The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $28.99 to $29.63 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]Board of Directors' non-qualified stock option grant that vested in full May 26, 2017.
- [F3]Board of Directors' non-qualified stock option grant that vested in full September 1, 2024.
- [F4]Board of Directors' non-qualified stock option grant that vested in full June 6, 2025.